Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) EPS (Basic) (2016 - 2026)

Sanofi's EPS (Basic) history spans 17 years, with the latest figure at $21.59 for Q1 2026.

  • On a quarterly basis, EPS (Basic) fell 84.69% to $21.59 in Q1 2026 year-over-year; TTM through Mar 2026 was $768.86, a 312.63% increase, with the full-year FY2025 number at $7.45, up 57.02% from a year prior.
  • EPS (Basic) hit $21.59 in Q1 2026 for Sanofi, up from -$1.18 in the prior quarter.
  • Over the last five years, EPS (Basic) for SNY hit a ceiling of $851.09 in Q2 2023 and a floor of -$1.18 in Q4 2025.
  • Historically, EPS (Basic) has averaged $159.46 across 5 years, with a median of $13.69 in 2022.
  • Biggest five-year swings in EPS (Basic): soared 8037.92% in 2024 and later crashed 726.69% in 2025.
  • Tracing SNY's EPS (Basic) over 5 years: stood at $9.36 in 2022, then plummeted by 103.75% to -$0.35 in 2023, then soared by 59.44% to -$0.14 in 2024, then crashed by 726.69% to -$1.18 in 2025, then surged by 1936.15% to $21.59 in 2026.
  • Business Quant data shows EPS (Basic) for SNY at $21.59 in Q1 2026, -$1.18 in Q4 2025, and $607.43 in Q3 2025.